Which has better earnings and valuation, NNVC or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Vivani Medical N/A N/A -$26.61M -$0.40 N/A

Is NNVC or VANI more profitable?

NanoViricides' return on equity of -87.90% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Vivani Medical N/A -218.52% -73.92%

Does the media favor NNVC or VANI?

In the previous week, Vivani Medical had 4 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Vivani Medical and 2 mentions for NanoViricides. Vivani Medical's average media sentiment score of 1.04 beat NanoViricides' score of 0.09 indicating that Vivani Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NNVC or NRXP more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% NRx Pharmaceuticals N/A N/A -202.92%

Does the media prefer NNVC or NRXP?

In the previous week, NRx Pharmaceuticals had 6 more articles in the media than NanoViricides. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 2 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.09 beat NRx Pharmaceuticals' score of 0.04 indicating that NanoViricides is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NNVC or CPIX?

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer NNVC or CPIX?

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 2 mentions for NanoViricides. Cumberland Pharmaceuticals' average media sentiment score of 0.85 beat NanoViricides' score of 0.09 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cumberland Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, PLYX or NNVC?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.05 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PLYX or NNVC more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Does the media favor PLYX or NNVC?

In the previous week, Polaryx Therapeutics had 4 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Polaryx Therapeutics and 2 mentions for NanoViricides. Polaryx Therapeutics' average media sentiment score of 1.21 beat NanoViricides' score of 0.09 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NNVC or RFL?

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Given NanoViricides' stronger consensus rating and higher probable upside, research analysts plainly believe NanoViricides is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NNVC or RFL more profitable?

NanoViricides has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Rafael -3,321.74% -41.27% -35.32%

NanoViricides (NNVC) Competitors

$1.38 +0.02 (+1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 -0.03 (-2.54%)

As of 07:36 PM Eastern

Compare

NNVC vs. VANI, NRXP, CPIX, PLYX, and RFL

Should you buy NanoViricides stock or one of its competitors? NanoViricides's main competitors and comparable companies include Vivani Medical (VANI), NRx Pharmaceuticals (NRXP), Cumberland Pharmaceuticals (CPIX), Polaryx Therapeutics (PLYX), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NanoViricides compare to Vivani Medical?

NanoViricides (NYSE:NNVC) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

NanoViricides' return on equity of -87.90% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Vivani Medical	N/A	-218.52%	-73.92%

In the previous week, Vivani Medical had 4 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Vivani Medical and 2 mentions for NanoViricides. Vivani Medical's average media sentiment score of 1.04 beat NanoViricides' score of 0.09 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NanoViricides has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

Vivani Medical is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 167.86%. Given NanoViricides' stronger consensus rating and higher probable upside, research analysts plainly believe NanoViricides is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

NanoViricides and Vivani Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does NanoViricides compare to NRx Pharmaceuticals?

NanoViricides (NYSE:NNVC) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, NRx Pharmaceuticals had 6 more articles in the media than NanoViricides. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 2 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.09 beat NRx Pharmaceuticals' score of 0.04 indicating that NanoViricides is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 955.05%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

NRx Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
NRx Pharmaceuticals	N/A	N/A	-202.92%

NanoViricides has higher earnings, but lower revenue than NRx Pharmaceuticals. NanoViricides is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
NRx Pharmaceuticals	$1.23M	96.32	-$28.62M	-$1.09	N/A

Summary

NanoViricides and NRx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does NanoViricides compare to Cumberland Pharmaceuticals?

NanoViricides (NYSE:NNVC) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

NanoViricides has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NanoViricides has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than NanoViricides. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Cumberland Pharmaceuticals	$44.52M	2.62	-$2.84M	-$0.71	N/A

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 2 mentions for NanoViricides. Cumberland Pharmaceuticals' average media sentiment score of 0.85 beat NanoViricides' score of 0.09 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cumberland Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cumberland Pharmaceuticals beats NanoViricides on 8 of the 15 factors compared between the two stocks.

How does NanoViricides compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

10.3% of NanoViricides shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Polaryx Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 194.87%. NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 334.78%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Polaryx Therapeutics had 4 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Polaryx Therapeutics and 2 mentions for NanoViricides. Polaryx Therapeutics' average media sentiment score of 1.21 beat NanoViricides' score of 0.09 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Polaryx Therapeutics beats NanoViricides on 7 of the 12 factors compared between the two stocks.

How does NanoViricides compare to Rafael?

NanoViricides (NYSE:NNVC) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

NanoViricides has higher earnings, but lower revenue than Rafael. NanoViricides is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Rafael	$920K	113.44	-$30.52M	-$0.68	N/A

In the previous week, NanoViricides had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for NanoViricides and 0 mentions for Rafael. NanoViricides' average media sentiment score of 0.09 beat Rafael's score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
Rafael	Neutral

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Given NanoViricides' stronger consensus rating and higher probable upside, research analysts plainly believe NanoViricides is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NanoViricides has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

NanoViricides has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Rafael	-3,321.74%	-41.27%	-35.32%

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NanoViricides beats Rafael on 10 of the 15 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$31.72M	$11.89B	$7.06B	$24.33B
Dividend Yield	N/A	2.70%	2.57%	3.68%
P/E Ratio	-1.92	775.15	269.06	30.78
Price / Sales	N/A	743.86	602.43	21.31
Price / Cash	N/A	66.45	70.48	32.80
Price / Book	2.09	11.60	12.91	6.82
Net Income	-$8.29M	$2.77B	$3.45B	$1.06B
7 Day Performance	-2.82%	0.17%	1.12%	0.55%
1 Month Performance	-22.03%	0.35%	1.79%	3.13%
1 Year Performance	-6.12%	161.52%	67.69%	18.71%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	1.8385 of 5 stars	$1.38 +1.5%	$6.00 +334.8%	-9.3%	$31.72M	N/A	N/A	20
VANI Vivani Medical	3.827 of 5 stars	$1.39 -1.4%	$3.75 +169.8%	+6.3%	$121.59M	N/A	N/A	20	News Coverage Positive News Earnings Report
NRXP NRx Pharmaceuticals	2.3084 of 5 stars	$3.40 +1.5%	$34.50 +914.7%	+32.0%	$121.37M	$1.23M	N/A	2	News Coverage Earnings Report Upcoming Earnings
CPIX Cumberland Pharmaceuticals	0.6213 of 5 stars	$7.96 +2.2%	N/A	+169.6%	$116.72M	$44.52M	N/A	80	Gap Down
PLYX Polaryx Therapeutics	4.4887 of 5 stars	$2.20 +3.8%	$8.50 +286.4%	N/A	$105.67M	N/A	N/A	11	News Coverage Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. VANI, NRXP, CPIX, PLYX, and RFL

How does NanoViricides compare to Vivani Medical?

Summary

How does NanoViricides compare to NRx Pharmaceuticals?

Summary

How does NanoViricides compare to Cumberland Pharmaceuticals?

Summary

How does NanoViricides compare to Polaryx Therapeutics?

Summary

How does NanoViricides compare to Rafael?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. VANI, NRXP, CPIX, PLYX, and RFL

How does NanoViricides compare to Vivani Medical?

Is NNVC or VANI more profitable?

Does the media favor NNVC or VANI?

Which has more risk and volatility, NNVC or VANI?

Which has better earnings and valuation, NNVC or VANI?

Do institutionals & insiders have more ownership in NNVC or VANI?

Do analysts prefer NNVC or VANI?

Summary

How does NanoViricides compare to NRx Pharmaceuticals?

Does the media prefer NNVC or NRXP?

Which has more risk & volatility, NNVC or NRXP?

Do insiders & institutionals hold more shares of NNVC or NRXP?

Do analysts prefer NNVC or NRXP?

Is NNVC or NRXP more profitable?

Which has preferable valuation & earnings, NNVC or NRXP?

Summary

How does NanoViricides compare to Cumberland Pharmaceuticals?

Is NNVC or CPIX more profitable?

Do analysts prefer NNVC or CPIX?

Which has more volatility and risk, NNVC or CPIX?

Which has better valuation and earnings, NNVC or CPIX?

Does the media prefer NNVC or CPIX?

Do institutionals & insiders hold more shares of NNVC or CPIX?

Summary

How does NanoViricides compare to Polaryx Therapeutics?

Is PLYX or NNVC more profitable?

Which has better valuation and earnings, PLYX or NNVC?

Do insiders & institutionals hold more shares of PLYX or NNVC?

Do analysts prefer PLYX or NNVC?

Does the media favor PLYX or NNVC?

Summary

How does NanoViricides compare to Rafael?

Which has higher valuation & earnings, NNVC or RFL?

Does the media prefer NNVC or RFL?

Do analysts rate NNVC or RFL?

Which has more risk & volatility, NNVC or RFL?

Is NNVC or RFL more profitable?

Do institutionals and insiders hold more shares of NNVC or RFL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools